JUBLPHARMA vs STAR: Stock Comparison

Jubilant Pharmova Limited vs Strides Pharma Science Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Jubilant Pharmova Limited is the larger company by market capitalisation. Jubilant Pharmova Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Strides Pharma Science Limited shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Jubilant Pharmova Limited and Strides Pharma Science Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, JUBLPHARMA is more favourable on 5 of 13 scored metrics and STAR on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
JUBLPHARMA is the larger company
₹15,512 Cr vs ₹9,516 Cr
P/E Ratio
STAR has a lower P/E
17.37x vs 39.79x
P/B Ratio
JUBLPHARMA has a lower P/B
2.24x vs 3.11x
EPS
STAR has higher earnings per share
₹60.31 vs ₹25.05
Dividend Yield
JUBLPHARMA has a higher dividend yield
0.52% vs 0.37%
Revenue Growth (TTM YoY)
JUBLPHARMA has faster revenue growth
18.7% vs 11.2%
EPS Growth (TTM YoY)
STAR has faster EPS growth
54.4% vs -22.4%
Qtr Sales Growth
JUBLPHARMA has stronger quarterly sales growth
18.7% vs 11.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricJUBLPHARMASTAR
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricJUBLPHARMASTAR
Live Price₹996₹1,039.6
Day Change-1.17%-1.11%
Volume87,3932.32 L
52-Week High₹1,248₹1,231
52-Week Low₹786.05₹768.65
Distance from 52W High-20.19%-15.55%

Valuation

MetricJUBLPHARMASTAR
Market Cap₹15,512 Cr₹9,516 Cr
P/E Ratio39.79x17.37x
P/B Ratio2.24x3.11x
EPS₹25.05₹60.31
Book Value₹448.5₹337.09
Dividend Yield0.52%0.37%

Growth

MetricJUBLPHARMASTAR
Revenue Growth (TTM YoY)18.7%11.2%
EPS Growth (TTM YoY)-22.4%54.4%
Qtr Sales Growth18.7%11.2%
Qtr Profit Growth-17.4%28.1%

Profitability & Leverage

MetricJUBLPHARMASTAR
ROE6.55%20.4%
ROCE8.99%18.6%
Net Margin5.28%10.58%
Operating Margin15.2%19%
Debt to Equity0.51x0.57x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricJUBLPHARMASTAR
Promoter Holding44.39%27.91% 0.05 pp
FII Holding15.9% 0.06 pp28.68% 0.84 pp
DII Holding11.62% 0.4 pp14.45% 1.43 pp
Public Holding24.24% 0.33 pp28.95% 0.64 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Jubilant Pharmova Limited and Strides Pharma Science Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.